NASEM: Reduce cancer drug waste by reformulating development, payments, dosing

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Once an expensive cancer drug is discarded, it’s not worth it for drug developers, health care providers, and payers to recoup its cost, the National Academies of Sciences, Engineering, and Medicine said in a congressionally mandated report.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Alexandria Carolan
Alexandria Carolan
Reporter
Table of Contents

YOU MAY BE INTERESTED IN

Vinay Prasad, a MAHA-aligned hematologist-oncologist with an avid cyber following, was named director of the FDA Center for Biologics Evaluation and Research, where he will be responsible for the agency’s regulation of vaccines and biologics, including cell and gene therapies.
Alexandria Carolan
Alexandria Carolan
Reporter

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login